Iovance Biotherapeutics, Inc. (IOVA)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc.  ("Iovance" or "the Company") (NASDAQ: IOVA). The investigation concerns whether Iovance and certain of its officers and/or directors have violated federal securities laws.


On October 5, 2020, post-market, Iovance issued a press release “provid[ing] a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma.”  Specifically, Iovance advised investors that “the Company and the [U.S. Food and Drug Administration] have not been able to agree on the required potency assays to fully define its TIL therapy, which is required as part of a BLA [Biologics License Application] submission.  The Company is continuing to refine the information from its current potency assays and simultaneously developing additional assays.  As a result of these developments, the BLA submission is not expected by the end of 2020.”  On this news, Iovance’s stock price fell $3.96 per share, or 12.35%, to close at $28.10 per share on October 6, 2020.


If you are aware of any facts relating to this investigation, or purchased Iovance shares,  you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.